Nectin Therapeutics has entered into a global license agreement with Immunome, Inc., granting Immunome exclusive rights to a panel of antibodies targeting an undisclosed pioneering target.
Immunome’s extensive experience in developing and commercializing groundbreaking therapies positions them as an ideal partner for this strategic collaboration.
This agreement marks a significant step forward in Nectin’s journey. This partnership will accelerate Nectin Therapeutics’ mission to bring innovative treatments to patients with unmet medical needs. It also enables Nectin to focus its resources on advancing its leading project, the anti-PVR program (NTX1088), which is currently in clinical trials targeting tumor types with high unmet needs.
